摘要
目的探讨临床药师在华法林不敏感患者个体化抗凝治疗中的作用。方法通过参与1例肾移植患者进行人工血管旁路移植术后使用华法林不敏感的抗凝治疗过程,分析该患者华法林不敏感的原因,参与药物治疗方案调整,对患者进行药学监护。结果患者同时服用的硫唑嘌呤、环孢素软胶囊和基因型(CYP2C9*1/*1和VKORC1-1639GA)是减弱华法林作用的主要因素。结论结合患者合并用药和基因型监测等因素为患者提供华法林个体化抗凝治疗,提高抗凝治疗的有效性和安全性。
Objective To explore the role of clinical pharmacists in individualized anticoagulant therapy in the patients who were insensitive to warfarin.Mehtods Through clinical pharmacists’participation in anticoagulation therapy of one prosthetic vessel bypass grafting patient after kidney transplantation,the reason for warfarin insensitivity was analyzed,the causes of warfarin insensitivity in this patient were analyzed,the adjustment of drug treatment scheme was involved,and the patients were monitored pharmacologically.Results The patient’s medications such as azathioprine and ciclosporin and genotype results(CYP2 C9*1/*1 and VKORC1-1639 GA)may be the reason of warfarin insensitivity.Conclusion Medications and genotype testing could provide patients with individualized warfarin anticoagulation and improve the effectiveness and safety of anticoagulant therapy.
作者
刘秀梅
都丽萍
梅丹
LIU Xiu-mei;DU Li-ping;MEI Dan(Department of Pharmacy,People’s Hospital of Zhengzhou,Zhengzhou 450003,Henan Province,China;Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第10期1042-1043,1048,共3页
The Chinese Journal of Clinical Pharmacology
基金
首都卫生发展科研专项基金资助项目(首发2018-3-4017)
中国医学科学院医学与健康科技创新工程项目基金资助项目(2017-I2M-1-011)